Litigation Details for City of Providence v. Bausch Health Companies Inc. (N.D. Cal. 2019)

City of Providence v. Bausch Health Companies Inc. (N.D. Cal. 2019)

Docket		Date Filed	2019-09-18
Court	District Court, N.D. California	Date Terminated	2020-04-09
Cause	15:1 Antitrust Litigation	Assigned To	William Haskell Alsup
Jury Demand	Plaintiff	Referred To
Patents	6,340,475; 6,488,962; 6,635,280; 6,723,340; 7,780,987; 8,323,692
Link to Docket	External link to docket

Details for City of Providence v. Bausch Health Companies Inc. (N.D. Cal. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-09-18				External link to document
2019-09-18	1	Complaint	,340 (the “340 Patent”) that expires on Oct. 25, 2021, 6,340,475 25 (the “475 Patent”) that expired …Book patent (the ‘692 Patent), as well as two non-Orange Book listed patents 19 (the ‘667 Patent and U.S…Assertio listed 4 patents on the 500 mg formulation (U.S. Patent Nos. 6,488,962 (the “962 Patent”) that…manufacturer’s patents and patent information for accuracy or trustworthiness. In 6 listing patents and patent…listed patent(s) and/or the patent is 9 invalid and unenforceable. By simply listing the patents in the	External link to document

Litigation Summary and Analysis for City of Providence v. Bausch Health Companies Inc. | 3:19-cv-05831

Last updated: February 5, 2026

Overview

The case City of Providence v. Bausch Health Companies Inc., filed in the District of Rhode Island, addresses allegations of opioid-related misconduct. Providence claims Bausch, through its subsidiary, failed to prevent misuse and downplayed addiction risks associated with opioids they marketed. The lawsuit emerged amid broader litigation targeting opioid manufacturers and distributors for contributions to the nationwide opioid crisis.

Case Background

• Parties Involved:

  • Plaintiff: City of Providence, Rhode Island
  • Defendant: Bausch Health Companies Inc., formerly Valeant Pharmaceuticals International Inc.

• Filing Date: October 2019

• Legal Basis: State law claims of public nuisance, unjust enrichment, and violations related to deceptive marketing of opioids.

Key Allegations

• Bausch Health marketed opioid products, primarily Bausch Opioids, knowing their addictiveness.
• The company allegedly engaged in deceptive practices by minimizing addiction risks.
• Marketplace practices contributed to the opioid epidemic, affecting public health and finances.

Legal Proceedings

• Claims:

  • Public nuisance under Rhode Island law.
  • Unjust enrichment due to economic gains from deceptive practices.
  • Violations of consumer protection statutes.

• Defenses:

  • Bausch disputed liability, arguing compliance with regulatory standards.
  • Contended that Providence's claims are barred by statutes of limitations and pre-emption.

• Progression:

  • The case moved through motions to dismiss, with Bausch challenging the adequacy of Providence’s allegations.
  • As of the latest update, the case remains active, with ongoing discovery.

Significant Developments

1. Summary Judgment Motions: Bausch moved to dismiss certain claims, claiming lack of causation and insufficient evidence of misconduct.
2. Classification as Non-Designated Mass Tort: The case is part of the larger wave of opioid litigations, with courts scrutinizing the scope of claims and defendant responsibilities.
3. Settlement Discussions: No public settlement announced; proceedings continue with potential for trial or settlement.

Legal Context and Broader Implications

• The case aligns with numerous opioid litigations consolidating claims against manufacturers in federal and state courts.
• Providence's claims echo common themes: marketing practices, consumer deception, and public health impacts.
• Bausch’s strategies include aggressive motions focusing on legal technicalities to limit liability.

Litigation Status as of 2023

• The case is one of over 2,600 similar opioid-related cases filed nationwide[1].
• Neither party has indicated an imminent settlement.
• Trial dates are yet to be scheduled as of the latest court filings.

Analysis

• Legal Harbingers: The case tests the extent of manufacturer liability for public health crises rooted in alleged deceptive marketing.
• Potential Impact: Successful claims could increase manufacturer liabilities, influence regulatory oversight, and shift settlement dynamics.
• Challenges: Establishing causation remains complex; courts require detailed evidence linking specific marketing practices to actual addiction outcomes.

Key Takeaways

• Providence's case underscores the ongoing legal accountability efforts against opioid manufacturers.
• The case reflects the broader trends of state and municipal litigations addressing public nuisances caused by opioid marketing.
• Legal arguments focus on deceptive practices and their public health ramifications.
• The case's outcome could influence future litigation strategies and settlement negotiations for similar cases.
• Courts continue to scrutinize whether manufacturer conduct directly led to public harm, affecting the scope of damages and liability.

Frequently Asked Questions

1. What specific claims has Providence filed against Bausch?
   Public nuisance, unjust enrichment, and consumer protection violations related to opioid marketing practices.

2. Has Bausch Health admitted liability?
   No; Bausch has denied liability, asserting compliance with regulations and contesting causation claims.

3. What is the potential penalty or remedy sought?
   Typically involves monetary damages for public health costs and injunctive relief to curb deceptive practices.

4. Are other jurisdictions involved in similar litigation?
   Yes; over 2,600 opioid cases nationwide, including state and local governments, are part of coordinated and individual suits.

5. What is the potential impact of this case?
   Documented success could increase manufacturer accountability, influence settlement negotiations, and shape future legal standards.

---

References

[1] Bloomberg Law, "Opioid Litigation Tracker," accessed 2023.